Company’s 36-month beta value is 0.92.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NARI is 49.58M, and currently, short sellers hold a 8.05% ratio of that floaft. The average trading volume of NARI on April 19, 2024 was 1.18M shares.
NARI) stock’s latest price update
Inari Medical Inc (NASDAQ: NARI) has experienced a decline in its stock price by -0.16 compared to its previous closing price of 38.70. However, the company has seen a fall of -6.94% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-17 that IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
NARI’s Market Performance
NARI’s stock has fallen by -6.94% in the past week, with a monthly drop of -14.61% and a quarterly drop of -33.40%. The volatility ratio for the week is 3.63% while the volatility levels for the last 30 days are 4.47% for Inari Medical Inc The simple moving average for the last 20 days is -11.05% for NARI’s stock, with a simple moving average of -33.18% for the last 200 days.
Analysts’ Opinion of NARI
Many brokerage firms have already submitted their reports for NARI stocks, with Piper Sandler repeating the rating for NARI by listing it as a “Neutral.” The predicted price for NARI in the upcoming period, according to Piper Sandler is $55 based on the research report published on February 29, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see NARI reach a price target of $72. The rating they have provided for NARI stocks is “Buy” according to the report published on January 23rd, 2024.
Robert W. Baird gave a rating of “Outperform” to NARI, setting the target price at $79 in the report published on July 19th of the previous year.
NARI Trading at -19.19% from the 50-Day Moving Average
After a stumble in the market that brought NARI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.22% of loss for the given period.
Volatility was left at 4.47%, however, over the last 30 days, the volatility rate increased by 3.63%, as shares sank -15.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.38% lower at present.
During the last 5 trading sessions, NARI fell by -6.94%, which changed the moving average for the period of 200-days by -31.84% in comparison to the 20-day moving average, which settled at $43.08. In addition, Inari Medical Inc saw -40.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NARI starting from Hoffman William, who sale 1,451 shares at the price of $40.00 back on Apr 16 ’24. After this action, Hoffman William now owns 999,782 shares of Inari Medical Inc, valued at $58,040 using the latest closing price.
Hill, Mitch C., the Chief Financial Officer of Inari Medical Inc, sale 6,000 shares at $40.96 during a trade that took place back on Apr 12 ’24, which means that Hill, Mitch C. is holding 181,294 shares at $245,760 based on the most recent closing price.
Stock Fundamentals for NARI
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 0.88 for the gross margin
The net margin for Inari Medical Inc stands at -0.0. The total capital return value is set at -0.0. Equity return is now at value -0.37, with -0.28 for asset returns.
Based on Inari Medical Inc (NARI), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 1.12. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -10.97.
Currently, EBITDA for the company is 7.11 million with net debt to EBITDA at -0.47. When we switch over and look at the enterprise to sales, we see a ratio of 4.52. The receivables turnover for the company is 7.04for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.09.
Conclusion
In a nutshell, Inari Medical Inc (NARI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
